Abbvie takes over Novo Holdings portfolio company

Syndesi Therapeutics has been acquired by Abbvie in a USD 1bn deal.

Photo: PR / Novo Seeds

After four years of ownership, Novo Holdings has decided to sell Belgian portfolio company Syndesi Therapeutics to Abbvie.

The deal may total up to USD 1bn, with a USD 130m upfront payment.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs